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Germany, Tartu, Estonia, Basel, Switzerland, Bergen, Norway, Amsterdam, The Netherlands, and Antwerp, BelgiumBackground: Cross-sectional studies have reported a lower
prevalence of sensitization in older adults, but few longitudinal
studies have examined whether this is an aging or a year-of-
birth cohort effect.
Objective: We sought to assess changes in sensitization and total
IgE levels in a cohort of European adults as they aged over a
20-year period.
Methods: Levels of serum specific IgE to common aeroallergens
(house dust mite, cat, and grass) and total IgE levels were
measured in 3206 adults from 25 centers in the European
Community Respiratory Health Survey on 3 occasions over
20 years. Changes in sensitization and total IgE levels were
analyzed by using regression analysis corrected for potential
differences in laboratory equipment and by using inverse
sampling probability weights to account for nonresponse.
Results: Over the 20-year follow-up, the prevalence of
sensitization to at least 1 of the 3 allergens decreased from
29.4% to 24.8% (24.6%; 95% CI, 27.0% to 22.1%). The
prevalence of sensitization to house dust mite (24.3%; 95% CI,
26.0% to 22.6%) and cat (22.1%; 95% CI, 23.6% to 20.7%)
decreased more than sensitization to grass (20.6%; 95% CI,
22.5% to 1.3%). Age-specific prevalence of sensitization to
house dust mite and cat did not differ between year-of-birth
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significantly (geometric mean ratio, 0.63; 95% CI, 0.58-0.68) at
all ages in all year-of-birth cohorts.
Conclusion: Aging was associated with lower levels of
sensitization, especially to house dust mite and cat, after the age
of 20 years. (J Allergy Clin Immunol 2015;nnn:nnn-nnn.)
Key words: Allergens, sensitization, cohort study, epidemiology,
IgE, longitudinal analysis, aging, immunosenescence
Population-based cross-sectional studies have shown that the
prevalence of sensitization is higher in younger than in older age
groups.1-4 Although there have been year-of-birth cohort-related
increases in atopy over the last decades, it is hypothesized that
these cross-sectional observations might reflect decreases in
sensitization with aging-related immunosenescence. Longitudi-
nal studies that have performed skin prick tests or measured
serum allergen-specific IgE levels at baseline and follow-up
over periods of up to 14 years have reported that sensitization
increased with aging, although changes were less evident in
middle-aged and older adults.2,5-7 Two recent longitudinal studies
reported no change or a slight decrease in sensitization with
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Within the European Community Respiratory Health Survey
(ECRHS),9 a multicenter cohort study of more than 6000 young
and middle-aged adults followed for a 10-year period, there was
little evidence of substantial change in sensitization to at least 1
of cat, grass, or house dust mite (as measured based on serum spe-
cific IgE levels) over time as the cohort aged. The age-specific
prevalence of sensitization to grass but not to the other allergens
measured was higher in more recent year-of-birth cohorts. At the
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Completion of the third phase of the ECRHS has allowed
assessment of serum specific IgE levels on 3 occasions: baseline
and 10- and 20-year follow-up. The aims of this report were to (1)
assess the changes in IgE sensitization and total IgE levels in this
population-based cohort of European adults over a period of
20 years and (2) to investigate whether these changes were
different between year-of-birth cohorts.METHODS
Study participants
This is a multicenter population-based cohort study. Detailed descriptions
of the methods for ECRHS I and ECRHS II have been published
elsewhere.10,11 In ECRHS I 1500 men and 1500 women aged 20 to 44 years
were randomly recruited from community-based sampling frames in each cen-
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ECRHS I (1991-1993)
random sample of males and females (20-44 years)
25 centres (11 countries)
(N = 10,478)
ECRHS II (1998-2002)
(N = 5566)
. 2386 participants were lost to follow up
. 2526 participants took part in ECRHS II,
but did not provide blood samples 
. 887 participants were lost to follow up
. 1473 participants took part in ECRHS III,
but did not provide blood samples 
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AMARAL ET AL 3of responders was selected to complete an interviewer-led questionnaire
and provided a blood sample (1991-1993). In the majority of centers, an
additional sample of patients with symptoms highly suggestive of asthma
were recruited for the study, but these participants are not included in the
present analysis.
In ECRHS II (1998-2002) participants who had completed the extended
questionnaire in ECRHS I were reinvestigated and again provided a blood
sample. In ECRHS III those who took part in the clinical stages of ECRHS I
and II were again contacted, with responders invited to a local testing center
where blood samples were taken once more (2008-2013).
Eleven countries are represented in this report: Iceland (Reykjavik),
Norway (Bergen), Sweden (Gothenburg, Umea, and Uppsala), Estonia
(Tartu), Belgium (Antwerp South and Antwerp City), Germany (Hamburg
and Erfurt), the United Kingdom (Ipswich and Norwich), France (Bordeaux,
Grenoble, Montpelier, and Paris), Spain (Barcelona, Galdakao, Albacete,
Oviedo, and Huelva), Italy (Pavia, Turin, and Verona), and Australia
(Melbourne).
Ethical approval for the study from local research ethics committees and
written consent from participants were obtained.
ECRHS III (2008-2013)
(N = 3206)
FIG 1. Participant flow in the ECRHS. Only centers that took part in all 3
surveys are included.Measurement of IgE levels
In all 3 surveys blood samples were obtained and processed under similar
conditions. After clotting and centrifuging, serum was stored at 2208C until
analysis in a single central laboratory (Pharmacia Uppsala in 1992, Kings
College London in 2002, and AMC Amsterdam in 2013/2014) by using the
Phadia ImmunoCAP system (now Thermo Fisher Scientific, Uppsala,
Sweden).
To assess the effects of potential laboratory bias on the prevalence of IgE
sensitization and the mean of total IgE estimates, we conducted duplicate
assays on 794 samples (tested at ECRHS I, stored, and tested at ECRHS II) and
475 samples (tested at ECRHS II, stored, and tested at ECRHS III; see Table
E1 in this article’s Online Repository at www.jacionline.org). Themethods for
this correction are described in detail in the Methods section in this article’s
Online Repository at www.jacionline.org.Outcomes
Participants were considered sensitized if allergen-specific IgE to
Dermatophagoides pteronyssinus (house dust mite), Felis silvestris catus (cat),
and Phleum pratense (Timothy grass) was present in concentrations of
greater than 0.35 kUA/L. A higher threshold (>0.70 kUA/L) was also
considered. Atopy was defined as being sensitized to 1 of either house dust
mite, grass, or cat. Total IgE, expressed in kilounits/liters, was log-transformed
and considered as a continuous outcome for estimation of geometric means
(GMs) and their ratios.Statistical methods
Statistical analyses were performed with Stata software (version 13;
StataCorp LP, College Station, Tex). Analyses were restricted to the 3206
participants with information on serum specific IgE and total IgE levels in all 3
ECRHSs (Fig 1). Inverse sampling probability weights were used to standardize
the estimation from this population with data on IgE assays from all 3 ECRHSs
to the original target population of participants with data on IgE assays from
ECRHS I (see theMethods section in this article’s Online Repository for details
on the inverse sampling probability weighted estimation).
The prevalence of sensitization at each survey was determined by using
logistic regression with Huber variances considering participants as the
clusters. CIs for prevalences and their differences (net change) between
ECRHS II and I, ECRHS III and II, and ECRHS III and I were estimated by
using the normalizing hyperbolic arctangent transformation.12 Similarly, by
using linear regression, we calculated GM ratios of total IgE levels between
ECRHS II and I, ECRHS III and II, and ECRHS III and I.
Statistical analyses for each outcome were performed in 2 ways by using
uncorrected models and models corrected for potential laboratory bias. Only
results of the corrected models are presented in this report. Because data camefrom multiple centers, we tested for between-center heterogeneity in the
uncorrected results by using the methods of Cochran.13
In a final step analyses were repeated as follows: (1) stratified by sex;
(2) restricted to lifetime nonsmokers; and (c) stratified by year-of-birth cohort.
For this latter step, year-of-birth cohorts were defined by date of birth
(1964-1973, 1954-1963, and 1944-1953). The ages of these participants at
January 1, 1992 (the approximate midpoint of ECRHS I data
collection), would have been as follows: 18 years <_ age < 28 years,
28 years <_ age < 38 years, and 38 years <_ age <_ 48 years, respectively.
Participants fromTartu, Estonia, were recruited at age 20-44 years in 1994 and
would have been less than 20 years old on January 1, 1992; hence 18 years is
the lower age limit. Members of each age cohort would have been 10 years
older on January 1, 2002 (during the ECRHS II data collection), and 20 years
older on January 1, 2012 (during the ECRHS III data collection). This
approach allowed comparison of earlier cohorts with later cohorts at
approximately the same ages.RESULTS
A total of 3,206 (30.6%) of the 10,478 participants who
provided a blood sample in the first survey took part and again
provided a sample in both ECRHS II and III. The median age of
participants in ECRHS I was 34.9 years (interquartile range,
28.6-40.5 years), half were males, and forty-five percent were
lifetime nonsmokers. There was variation between centers in the
proportion of participants who provided samples at ECRHS I and
then went on to provide samples at ECRHS II and ECRHS III
(minimum, 13.6% in Pavia; maximum, 58.6% in Reykjavik).
Factors associated with response were older age and being a
nonsmoker. Response was not associated with sensitization at
baseline, sex, and reporting of wheeze (see Table E2 in this
article’s Online Repository at www.jacionline.org), although
those who took part in all 3 surveys reported waking with
breathlessness less frequently.Net change in IgE sensitization and total IgE levels
Laboratory-corrected net changes in the prevalence of IgE
sensitization to each of the allergens and in GMs of total IgE
TABLE I. Net change in IgE sensitization to house dust mite, grass, and cat and total IgE levels over 20 years (n 5 3206)
Prevalence
(%), ECRHS I
Net change (95% CI),
ECRHS II vs I
P value for
heterogeneity
between centers
Net change (95% CI),
ECRHS III vs I
P value for heterogeneity
between centers
House dust mite
>0.35 kUA/L 16.6 20.7 (22.2 to 0.9) .051 24.3 (26.0 to 22.6) .71
>0.70 kUA/L 13.1 20.7 (21.9 to 0.4) .63 23.1 (24.5 to 21.7) .21
Grass
>0.35 kUA/L 17.0 0.5 (21.0 to 2.0) .048 20.6 (22.5 to 1.3) .009
>0.70 kUA/L 14.2 0.0 (21.3 to 1.3) .48 22.2 (23.8 to 20.6) .97
Cat
>0.35 kUA/L 8.8 20.9 (22.1 to 0.3) .14 22.1 (23.6 to 20.7) .09
>0.70 kUA/L 6.4 0.0 (21.0 to 1.1) .15 21.1 (22.2 to 0.1) .04
House dust mite, grass, or cat
>0.35 kUA/L 29.4 0.1 (22.0 to 2.1) .003 24.6 (27.0 to 22.1) .03
>0.70 kUA/L 24.2 20.6 (22.2 to 1.0) .11 24.6 (26.6 to 22.6) .17
GM, ECRHS I
GM ratio (95% CI),
ECRHS II vs I
P value for
heterogeneity
between centers
GM ratio (95% CI),
ECRHS III vs I
P value for heterogeneity
between centers
Total IgE (kU/L) 29.8 0.84 (0.78 to 0.90) <.001 0.63 (0.58 to 0.68) <.001
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4 AMARAL ET ALlevels over a period of 20 years are shown in Table I. Between
ECRHS I and ECRHS II, there was no significant change in the
prevalence of IgE sensitization to any of the allergens by using
either the low or high cutoff levels.
Over the 20 years of follow-up (ie, between ECRHS I and
ECRHS III), the prevalence of IgE sensitization to house
dust mite, cat, and at least 1 allergen decreased. By using the
0.35 kUA/L cutoff, the prevalence of sensitization to grass
remained stable, but when the 0.70 kUA/L cutoff was used, there
was evidence of a reduction in sensitization. These changes were
similar in men and women (see Table E3 in this article’s Online
Repository at www.jacionline.org).
For some estimates, there was evidence of heterogeneity
between countries, but no clear pattern in this variation was
observed by latitude (Fig 2), response rate (see Fig E1 in this
article’s Online Repository at www.jacionline.org), or prevalence
of sensitization at baseline (see Fig E2 in this article’s Online
Repository at www.jacionline.org).
Overall, there was a significant decrease in total IgE levels over
the 20 years of follow-up (GM ratio, 0.63; 95% CI, 0.58-0.68).
This generalized decrease in total IgE levels occurred in all
centers, although the magnitude of the change varied
(heterogeneity between centers, P < .001; see Fig E3 in this
article’s Online Repository at www.jacionline.org). Patterns
were similar in men and women (see Table E3).
Restriction of analyses to the 1304 participants who were
lifetime nonsmokers did not materially alter the results reported
above (see Table E4 in this article’s Online Repository at
www.jacionline.org).Association of net change with age and cohort
In ECRHS I the prevalence of IgE sensitization to house dust
mite, grass, cat, and at least 1 allergen was higher in younger
adults (ie, those born more recently) than in older adults
(Table II).
Over the 20-year period, the prevalence of sensitization to
house dust mite decreased in all age groups to a similar extent, andthere was little evidence that the age-specific prevalence of
sensitization to house dust mite was different between those born
more recently and those born earlier (Fig 3, A). Overall, the
picture was one of a decrease in sensitization with age, with
decreases occurring throughout adult life. This was broadly
similar for sensitization to cat (Fig 3, C). However, these patterns
were different for sensitization to grass. Although there was
evidence of a decrease in sensitization to grass in those who
were the oldest at recruitment (ie, the earlier cohort), decreases
were not seen in those who were born more recently. As a result,
there were marked differences in the age-specific prevalence of
sensitization to grass between cohorts with higher age-specific
prevalence in those born after 1964 (Fig 3, B). The prevalence
of IgE sensitization to at least 1 of house dust mite, grass, and
cat showed a pattern similar to that of sensitization to house
dust mite and cat. The most recent cohort had the highest
prevalence at younger ages, but these cohort-related differences
were not apparent in later adult life (Fig 3, D). Similar patterns
were observed when using the cutoff of 0.70 kUA/L (see Table
E5 in this article’s Online Repository at www.jacionline.org).
The population GM of total IgE was lower at each follow-up in
all cohorts over the 20-year period of follow-up, and the more
recent cohorts had lower total IgE levels than those born earlier at
the equivalent ages (Fig 4 and Table II).DISCUSSION
We have shown that the prevalence of sensitization to at least 1
of house dust mite, cat, or grass has decreased within a large
population-based adult cohort followed over a period of 20 years.
There was a decrease in the prevalence of sensitization to house
dust mite and cat, and the GM total IgE levels also decreased.
Sensitization to grass did not follow these patterns so clearly,
showing instead an increase at younger ages and aging effects
only at older ages.
The strengths of this study are the population-based nature of
the sample derived from several parts of Europe and Australia, the
prolonged period of follow-up, and the standardized handling and
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FIG 2. Net change in prevalence of IgE sensitization (cutoff, 0.35 kUA/L) to house dust mite
(I2 [heterogeneity] 5 0.0%, P 5 .71), grass (I2 5 44.9%, P 5 .009), cat (I2 5 29.0%, P 5 .09), and at least 1
of these allergens (I2 5 38.6%, P 5 .03). Centers are sorted by latitude (from north to south).
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AMARAL ET AL 5testing of samples between centers and over time. Changes in
laboratory staff, consumables, and methods between surveys
could lead to bias in prevalence estimates, and to address this, we
have used information from duplicate assays of hundreds ofsamples to adjust our estimates. As with all cohorts, there has
been attrition during the 20-year period of follow-up, and the
analyses we present are based on participants who have taken part
in all 3 phases of the study. We are aware that considerable loss to
TABLE II. Net change in IgE sensitization (>0.35 kUA/L) to house dust mite, grass, and cat and total IgE levels (kilounits per liter)
over 20 years by year-of-birth cohort
1964-1973 (n 5 736) 1954-1963 (n 5 1314) 1944-1953 (n 5 1156)
Prevalence
(%) or GM Net change (95% CI)
Prevalence
(%) or GM Net change (95% CI)
Prevalence
(%) or GM Net change (95% CI)
ECRHS I ECRHS II vs I ECRHS III vs I ECRHS I ECRHS II vs I ECRHS III vs I ECRHS I ECRHS II vs I ECRHS III vs I
House dust
mite
18.6 20.6 (23.0 to 1.8) 24.1 (26.7 to 21.5) 17.2 0.2 (21.9 to 2.4) 24.5 (26.9 to 22.1) 13.8 22.0 (23.9 to 20.1) 24.3 (26.6 to 21.9)
Grass 20.6 3.3 (0.4 to 6.2) 1.5 (21.8 to 4.9) 15.9 0.5 (21.4 to 2.3) 20.1 (22.5 to 2.3) 15.4 21.9 (23.8 to 0.0) 23.2 (25.3 to 21.0)
Cat 10.5 0.2 (22.2 to 2.6) 20.7 (23.5 to 2.0) 8.3 21.4 (22.9 to 0.1) 22.0 (23.6 to 20.3) 8.1 21.2 (22.7 to 0.2) 23.6 (25.2 to 22.0)
House dust mite,
grass, or cat
33.5 1.9 (21.3 to 5.1) 22.1 (26.1 to 1.9) 28.7 1.1 (21.6 to 3.7) 24.1 (27.2 to 21.1) 26.5 23.0 (25.6 to 20.3) 27.4 (210.4 to 24.3)
Total IgE 29.9 0.81 (0.72 to 0.91) 0.61 (0.54 to 0.68) 31.3 0.85 (0.78 to 0.92) 0.61 (0.56 to 0.67) 27.9 0.84 (0.78 to 0.92) 0.68 (0.61 to 0.75)
FIG 3. Prevalence of IgE sensitization to house dust mite (A), grass (B), cat (C), and at least 1 of these 3
allergens (D) over 20 years of follow-up by year-of-birth cohort.
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account for small differences between these subjects and the
initial cohort at baseline and to enhance the external validity of
our results, we have corrected our models with inverse sampling
probability weights. This method generates estimates that apply
to the population we sampled at baseline. We are unable to say
whether the start of the age-related decrease in sensitization
occurs around the age of 20 years or earlier because the ECRHS is
a cohort of adults only.To date, few other population-based studies have reported on
longitudinal changes in sensitization by measuring serum specific
IgE levels.6,8 These earlier reports, both from Denmark, are of
smaller samples and mostly over shorter time periods. Linneberg
et al6 studied changes over an 8-year period in serum specific IgE
levels to at least 1 of 6 allergens in about 400 adolescents and
adults in Copenhagen, reporting an increase in the prevalence
of IgE sensitization, especially among those born in the 1960s
or later. Older adults (>40 years, n 5 695) living in the same
Mid−survey age group (years)
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FIG 4. Changes in total IgE levels (kilounits per liter) over 20 years of
follow-up by year-of-birth cohort.
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AMARAL ET AL 7city and followed for 20 years showed no change in sensitization
over a 20-year period in prevalence of IgE sensitization to at least
1 of 19 allergens.8 Other studies looked at changes in sensitization
by performing skin prick tests and reported increases with
aging.2,4,5 However, skin prick tests are much more difficult to
standardize over different periods because they are prone to
fieldworker variation, with changes in skin prick test reagents
being difficult to assess.14,15
Barbee et al16 studied 1100 participants in the United States
and reported a decrease in total IgE levels with age in children
and young adults but not in older adults. In ECRHS total IgE
levels decreased with aging within each cohort, with more recent
cohorts having lower total IgE levels than earlier ones at the same
age. In a previous report we showed that smoking associated
differently with sensitization to different aeroallergens and in a
dose-response manner with total IgE levels.17 Therefore we
hypothesized that changes in sensitization over time could be
related to decreasing smoking rates and that lifetime nonsmokers
would not show changes in sensitization. Our present findings
show that a decrease in sensitization is unlikely to be related to
smoking cessation. The decrease in total IgE levels in our study
might in part be explained by a decrease in helminth infestation,
as observed by others in children.18
We saw no evidence of change in the prevalence of IgE
sensitization to house dust mite, cat, grass, and at least 1 of these 3
as the cohort aged over the initial 10 years of follow-up of the
ECRHS.9 This observation is confirmed within this second report,
but we go on to show that prevalence does decrease over 20 years
and appears greater when subjects are aged about 40 years or
older. This finding might be explained by immunosenescence,
which seems to be more evident after 50 years of age19 and
corresponds to age-related changes in the number and function
of cells from the immune system.20 The production of IgE, which
is dependent on an interaction between B and T cells,21 might
decrease as a consequence of the naturally occurring involution
of the thymus22; the thymic output of T cells per day in a
50-year-old is about 33% lower than that in a 25-year-old.22
Our findings are supported by animal studies, which suggest
that the production of IgE to an allergen challenge is higher in
younger than older animals.23,24 In one of these studies, thetransplantation of thymocytes into young (8 weeks old) mice
resulted in no change in IgE response, whereas that into aged
(65 weeks old) mice resulted in an enhanced IgE response similar
to that into young mice.24
One might expect all markers of atopy to follow similar
age/period/cohort patterns. Our report suggests house dust mite
and cat might be different to grass, but we can only speculate as to
the reason for this. One explanation for the decrease in
sensitization to house dust mite and cat could be avoidance by
the participants. We cannot assess whether participants avoided
house dust mite allergen, but we do know that the prevalence of
cat ownership among those with IgE at all 3 time points has not
decreased over the 20 years of follow-up (16.9% at ECRHS I and
19.5% at ECRHS III). This supports the hypothesis that the
decrease in prevalence of sensitization to cat is more likely due to
aging-related immunosenescence. There are differences in the
epidemiology of sensitization to each of the 3 allergens,
particularly with respect to factors associated with the hygiene
hypothesis. Larger sibships protect younger siblings from hay
fever and sensitization to grass more strongly than from asthma
and sensitization to house dust mites.25,26 Decreasing family size
over the last decades might explain the less marked aging effect
for grass than for other allergens. Changes in the level of exposure
to pollensmight have had a role in our findings.27,28 There are also
reports suggesting that pollens in our more modern society are
more allergenic than they have been previously,29,30 which could
be related to the high levels of air pollutants, such as ozone,
nitrogen dioxide, and carbon dioxide.30-32 The presence of
unmeasured factors might also have a role in the different patterns
observed in sensitization to the 3 allergens.
In summary, over a period of 20 years, the prevalence of
specific IgE sensitization to house dust mite and cat, but not grass,
significantly decreased in the multinational cohort of adults from
the ECRHS as a consequence of aging, beingmore evident among
those aged 40 years or older.
We thank the participants, field workers, and data managers of this study for
their time and cooperation.
Key messages
d Allergen-specific and total IgE levels decrease after the
age of 20 years as subjects become older.
d Kinetics of IgE sensitization decrease differently for
different allergens and might be faster after 40 years of
age.
d The biological mechanism and environmental determi-
nants for IgE sensitization that decrease with aging
need to be explored so that we can improve our under-
standing of the cause of atopy and atopic diseases.REFERENCES
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METHODS
Statistical analyses were performed with Stata software (version 13,
StataCorp LP).
Laboratory bias (duplicate measurements)
To assess the effects of potential laboratory bias on the prevalence of IgE
sensitization and the mean of total IgE estimates, we conducted duplicate
assays on 794 samples (tested at ECRHS I, stored, and tested at ECRHS II) and
475 samples (tested at ECRHS II, stored, and tested at ECRHS III). CIs for
Cohen k statistics for each comparison between 2 measurements of the same
sample were computed by using the kap command in Stata together with delta
method SEs by using the normalizing and variance-stabilizing transformation
ln(1-k) (see Table E1).
Elimination of laboratory bias
To correct our estimates for laboratory bias, we included the following in
the models:
 the 3 main-assessment assays for each participant (GMs or odds for
each combination of center and ECRHS);
 4 extra parameters (GM ratios or odds ratios) regarding the paired
method-comparison assays: 2 indicating an assay’s membership in
the 2 method-comparison studies and 2 indicating that an assay was
carried out by using the ECRHS II or III methods, respectively, instead
of the ECRHS I methods.
Analysis of outcomes. To determine the difference in prevalence
of sensitization and GM ratios of total IgE levels between surveys, we used the
‘margins’ and ‘nlcom’ commands and the ‘regpar’ add-on package,E1 as
required.
Inverse sampling probability weighted estimation
Inverse sampling probability weights were used to standardize the
estimation from the population with data on IgE assays in all 3 ECRHSs to
REFERENCES
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a target population of participants with data on IgE assays from ECRHS I,
which was randomly sampled from the general adult population in different
European and Australian centers.
The inverse sampling probability weights were calculated by using a
logistic regression model,E2 with a separate set of parameters for each center
with any IgE data responders, predicting response to all 3 surveys from
baseline characteristics adapted from the response regression model of Jarvis
et al.E3 The parameters for each center were baseline odds; an exponential
per-decade odds ratio for age at January 1, 1992; an odds ratio for female
sex (compared with a baseline of male sex); odds ratios for self-reported
smoking status at ECRHS I (exsmoker and current smoker compared with a
baseline of never smoker); an odds ratio for wheeze at ECRHS I; an odds ratio
for waking with shortness of breath at ECRHS I; and an odds ratio for IgE
sensitization to house dust mite, cat, or grass at ECRHS I. When we
meta-analyzed the parameters using random-variable-effects meta-analysis,E4
we found that participants who have taken part in all 3 phases of the studywere
slightly older, less likely to be smokers, and less likely to have reported
shortness of breath than participants who did not have serum IgE in all 3
surveys (Table E2).
Use of inverse sampling probability weights to standardize the estimates to
the target population in ECRHS I seemed towork, as indicated by a Somers’ D
of the response-propensity scoreE5 with respect to a response of 0.008 when
inverse sampling probability weighted versus one of 0.239 when unweighted.
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FIG E1. Net change in prevalence of IgE sensitization (cutoff, 0.35 kUA/L) to house dust mite, grass, cat, and
at least 1 of these allergens. Centers are sorted by descending response rate.
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FIG E2. Net change in prevalence of IgE sensitization (cutoff, 0.35 kUA/L) to house dust mite, grass, cat, and
at least 1 of these allergens. Centers are sorted by ascending prevalence of sensitization at baseline.
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Geometric mean ratio of total IgE over 20 years of follow up (ECRHS III vs I), with 95% CI and N of subjects 
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FIG E3. Net change in GM ratio of total IgE levels (kilounits per liter). Centers were sorted by latitude
(north to south; left) and descending response rate (right).
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TABLE E1. Results from a comparability study in which replicate samples from 1992 were tested in 2002 and replicate samples from 2002 were tested in 2013/2014
IgE in 1992 IgE in 2002
Difference (%),
2002 vs 1992 (95% CI),
n 5 794 Cohen k,
2002 vs 1992
IgE in 2002 IgE in 2013/2014
Difference (%),
2013/2014 vs
2002 (95% CI),
n 5 475 Cohen k,
2013/2014 vs 2002No. (of 794) Percent No. (of 794) Percent No. (of 475) Percent No. (of 475) Percent
House dust mite
0.35 kUA/L 241 30.4 247 31.1 0.8 (21.3 to 2.8) 0.80 129 27.2 133 28.0 0.8 (20.6 to 2.3) 0.94
0.70 kUA/L 193 24.3 195 24.6 0.3 (21.1 to 1.6) 0.89 106 22.3 104 21.9 20.4 (21.4 to 0.6) 0.96
Grass
0.35 kUA/L 229 28.8 224 28.2 20.6 (22.3 to 1.1) 0.86 119 25.1 115 24.2 20.8 (22.1 to 0.5) 0.94
0.70 kUA/L 187 23.6 196 24.7 1.1 (20.3 to 2.6) 0.88 99 20.8 98 20.6 20.2 (21.6 to 1.2) 0.93
Cat
0.35 kUA/L 116 14.6 133 16.8 2.1 (0.7 to 3.6) 0.83 60 12.6 63 13.3 0.6 (20.7 to 2.0) 0.90
0.70 kUA/L 94 11.8 102 12.8 1.0 (20.3 to 2.3) 0.85 51 10.7 54 11.4 0.6 (20.5 to 1.7) 0.92
Sensitization to
>_1 allergen
0.35 kUA/L 336 42.3 338 42.6 0.3 (21.8 to 2.3) 0.82 182 38.3 186 39.2 0.8 (20.9 to 2.6) 0.92
0.70 kUA/L 278 35.0 293 36.9 1.9 (0.4 to 3.4) 0.89 159 33.5 162 34.1 0.6 (20.7 to 2.0) 0.95
GM in 1992,
n 5 794
GM in 2002,
n 5 794
GM ratio,
2002 vs 1992
(95% CI)
GM in 2002,
n 5 475
GM in 2013/2014,
n 5 475
GM ratio,
2013/14 vs 2002
(95% CI)
Total IgE
(kU/L)
36.1 52.75 1.46 (1.38-1.55) 42.7 43.2 1.01 (0.98-1.05)
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TABLE E2. Baseline characteristics of subjects with IgE measurements in all 3 ECRHSs versus subjects with IgE measurements in
baseline survey only from same centers
With IgE measurements in
baseline survey only (n 5 7272)
With IgE measurements in all
3 surveys (n 5 3206)
Adjusted* odds for
responding (95% CI)
P value for
heterogeneityz
Age at baseline (per 10 y) — — 1.40 (1.29-1.52) .036
Female sex (%) 49.9 50.0 1.00 (0.19-1.11) .17
Smoking status at baseline (%)
Lifetime nonsmoker 41.6 45.1 1.00
Exsmoker 21.1 22.6 0.88 (0.78-1.01) .29
Current smoker 37.3 32.3 0.65 (0.58-0.73) .38
Symptoms in the last 12 mo
Wheeze 22.2 19.8 0.97 (0.84-1.11) .12
Woken with shortness of breath 6.4 4.8 0.76 (0.61-0.94) .40
Sensitized to >_1 allergen (%) 29.5 27.9 1.05 (0.91-1.22) .0017
*From meta-analysis by center, adjusting for all other factors in the table.
House dust mite, cat, or grass.
From random-effects meta-analysis.
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TABLE E3. Net change in IgE sensitization to house dust mite, grass, and cat and total IgE levels over 20 years by sex
Male subjects (n 5 1604) Female subjects (n 5 1602)
Prevalence (%),
ECRHS I
Net change
(95% CI),
ECRHS
II vs I
P value for
heterogeneity
between
centers
Net change
(95% CI),
ECRHS III vs I
P value for
heterogeneity
between
centers
Prevalence
(%), ECRHS I
Net change
(95% CI),
ECRHS II vs I
P value for
heterogeneity
between
centers
Net change
(95% CI),
ECRHS III vs I
P value for
heterogeneity
between centers
House dust mite
>0.35 kUA/L 19.7 20.5 (22.7 to 1.6) .20 25.0 (27.2 to 22.8) .59 13.5 20.8 (22.5 to 0.9) .038 23.7 (25.7 to 21.7) .34
>0.70 kUA/L 15.1 20.3 (22.0 to 1.4) .95 22.9 (24.9 to 20.9) .26 11.0 21.1 (22.3 to 0.1) .096 23.3 (25.0 to 21.6) .057
Grass
>0.35 kUA/L 18.5 0.4 (21.6 to 2.4) .18 20.9 (23.2 to 1.3) .11 15.6 0.6 (21.2 to 2.4) .94 20.2 (22.5 to 2.1) .74
>0.70 kUA/L 15.8 20.3 (22.0 to 1.5) .16 23.1 (25.1 to 21.0) .82 12.7 0.3 (21.2 to 1.8) .91 21.3 (23.3 to 0.6) .95
Cat
>0.35 kUA/L 8.7 20.3 (21.9 to 1.3) .21 22.1 (23.8 to 20.4) .40 8.9 21.5 (22.9 to 20.1) .54 22.2 (23.9 to 20.5) .074
>0.70 kUA/L 6.4 0.2 (21.2 to 1.6) .22 21.2 (22.7 to 0.3) .27 6.4 20.1 (21.4 to 1.1) .071 21.0 (22.3 to 0.4) .013
House dust mite,
grass, or cat
>0.35 kUA/L 32.5 0.8 (21.8 to 3.5) .74 25.6 (28.6 to 22.5) .39 26.2 20.7 (23.0 to 1.6) .46 23.6 (26.4 to 20.7) .089
>0.70 kUA/L 26.5 0.3 (22.0 to 2.5) .81 24.6 (27.2 to 22.0) .25 21.9 21.5 (23.2 to 0.3) .40 24.5 (26.8 to 22.2) .056
GM, ECRHS I
GM ratio (95% CI),
ECRHS II vs I
P value for
heterogeneity
between centers
GM ratio (95% CI),
ECRHS III vs I
P value for
heterogeneity
between centers
GM,
ECRHS I
GM ratio (95% CI),
ECRHS II vs I
P value for
heterogeneity
between centers
GM ratio (95% CI),
ECRHS III vs I
P value for
heterogeneity
between centers
Total IgE (kU/L) 34.3 0.82 (0.75 to 0.88) <.001 0.65 (0.59 to 0.71) <.001 26.0 0.86 (0.79 to 0.93) .004 0.61 (0.56 to 0.67) <.001
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TABLE E4. Net change in IgE sensitization to house dust mite, grass, and cat and total IgE levels over 20 years: persistent lifetime
nonsmokers only (n 5 1304)
Prevalence
(%), ECRHS I
Net change (95% CI),
ECRHS II vs I
P value for heterogeneity
between centers
Net change (95% CI),
ECRHS III vs I
P value for heterogeneity
between centers
House dust mite
>0.35 kUA/L 15.8 0.0 (21.9 to 2.0) .005 23.4 (25.5 to 21.4) .08
>0.70 kUA/L 12.4 20.9 (22.2 to 0.5) .79 22.0 (23.8 to 20.2) .41
Grass
>0.35 kUA/L 20.5 1.1 (21.0 to 3.3) .75 20.4 (23.0 to 2.2) .26
>0.70 kUA/L 17.9 0.2 (21.6 to 2.1) .65 22.5 (24.9 to 20.1) .98
Cat
>0.35 kUA/L 10.5 20.6 (22.3 to 1.1) .78 22.0 (24.1 to 0.0) .42
>0.70 kUA/L 8.0 0.4 (21.2 to 2.0) .71 20.8 (22.5 to 1.0) .42
House dust mite, grass, or cat
>0.35 kUA/L 31.4 1.9 (20.8 to 4.5) .002 22.9 (26.0 to 0.2) .03
>0.70 kUA/L 26.7 0.1 (21.9 to 2.2) .21 23.3 (25.9 to 20.6) .21
GM, ECRHS I
GM ratio (95% CI),
ECRHS II vs I
P value for heterogeneity
between centers
GM ratio (95% CI),
ECRHS III vs I
P value for heterogeneity
between centers
Total IgE (kU/L) 27.8 0.82 (0.75 to 0.89) <.001 0.62 (0.56 to 0.68) <.001
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TABLE E5. Net change in IgE sensitization (>0.70 kUA/L) to house dust mite, grass, and cat over 20 years by birth cohort
1964-1973 (n 5 736) 1954-1963 (n 5 1314) 1944-1953 (n 5 1156)
Prevalence (%) Net change (95% CI) Prevalence (%) Net change (95% CI) Prevalence (%) Net change (95% CI)
ECRHS I ECRHS II vs I ECRHS III vs I ECRHS I ECRHS II vs I ECRHS III vs I ECRHS I ECRHS II vs I ECRHS III vs I
House dust mite 15.0 0.3 (21.9 to 2.4) 21.5 (-4.2 to 1.2) 14.1 20.9 (22.6 to 0.8) 24.4 (26.4 to 22.4) 9.9 21.3 (22.7 to 0.0) 22.7 (24.5 to 20.9)
Grass 18.2 1.7 (20.8 to 4.2) 20.7 (23.7 to 2.4) 13.8 0.1 (21.6 to 1.7) 22.2 (24.3 to 20.2) 11.4 21.6 (23.2 to 0.0) 23.5 (25.3 to 21.7)
Cat 7.7 1.0 (21.2 to 3.1) 20.1 (22.3 to 2.1) 5.8 20.3 (21.5 to 0.9) 20.8 (22.2 to 0.7) 5.9 20.3 (21.6 to 1.0) 22.3 (23.6 to 21.0)
House dust mite,
grass, or cat
29.5 1.2 (21.7 to 4.1) 22.3 (26.0 to 1.4) 24.1 20.6 (22.7 to 1.6) 25.4 (27.9 to 22.9) 19.6 22.2 (24.2 to 20.3) 25.4 (27.8 to 23.1)
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